Infection and Chemotherapy最新文献

{"title":"Late-Onset Granulomatous <i>Pneumocystis jirovecii</i> Pneumonia in A Renal Transplant Recipient: A Clinical Grand Round Conference Case in 2022.","authors":"Yae Jee Baek,&nbsp;Kyeongmin Kim,&nbsp;Bo Da Nam,&nbsp;Jongtak Jung,&nbsp;Eunjung Lee,&nbsp;Hyunjin Noh,&nbsp;Tae Hyong Kim","doi":"10.3947/ic.2023.0084","DOIUrl":"https://doi.org/10.3947/ic.2023.0084","url":null,"abstract":"<p><p>Late-onset <i>Pneumocystis jirovecii</i> pneumonia (PCP) can be developed in solid organ transplant (SOT) patients. Granulomatous <i>P. jirovecii</i> pneumonia (GPCP) can occur in immunocompromised patients, but has rarely been reported in SOT recipients. The diagnosis of GPCP is difficult since the sensitivity of sputum and bronchoalveolar lavage is low and atypical patterns are shown. A 60-year-old man, who had undergone renal transplantation 24 years ago presented with nodular and patchy lung lesions. He was asymptomatic and stable. After empirical treatment with a fluoroquinolone, the condition partially resolved but relapsed 4 months later. The pulmonary nodule was resected, and GPCP was confirmed. The pathogenesis of GPCP remains unclear, but in SOT recipients presenting with an atypical lung pattern, GPCP should be considered. This case was discussed at the Grand Clinical Ground of the Korean Society of Infectious Disease conference on November 3, 2022.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/5f/ic-55-309.PMC10551715.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41179280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resistance Trends of Antiretroviral Agents in People with Human Immunodeficiency Virus in Korea, 2012 - 2020.","authors":"Sang-Min Oh,&nbsp;Ji Hwan Bang,&nbsp;Sang-Won Park,&nbsp;Eunyoung Lee","doi":"10.3947/ic.2022.0150","DOIUrl":"10.3947/ic.2022.0150","url":null,"abstract":"<p><strong>Background: </strong>Domestic data on antiretroviral drug (ARV) resistance are limited, while alterations in ARV resistance are expected as the incidence of human immunodeficiency virus (HIV) infection increases. We evaluated the ten-year change in ARV resistance in people with HIV (PWH) in Korea.</p><p><strong>Materials and methods: </strong>Adults aged ≥19 years and diagnosed with HIV infection between January 2010 and December 2020 at a 750-bed municipal hospital were retrospectively reviewed. Data on clinical characteristics and resistance mutation test results were collected. The study population was divided into three-year intervals according to diagnosed year and their clinical characteristics were compared.</p><p><strong>Results: </strong>A total of 248 PWH were analyzed, and ARV resistance was detected in 30 of them (12.1%). Resistance was detected most frequently in PWH aged ≤29 years (16, 6.5%), and the median percentage of resistance detection per year was 14.3% (interquartile range, 12.7 - 16.1). The trend of the overall prevalence of ARV resistance mutations slightly decreased and then increased over time (15.3% in 2012 - 2014, 9.6% in 2015 - 2017, and 12.9% in 2018 - 2020). The prevalence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance markedly decreased over time (15.3% in 2012 - 2014, 8.7% in 2015 - 2017, and 2.4% in 2018-2020), while that of protease inhibitor (PI) and integrase strand transfer inhibitor (INSTI) increased from 0 until 2018 to 3.5% and 8.2% in 2018 - 2020, respectively.</p><p><strong>Conclusion: </strong>The trend of NNRTI resistance has decreased over time, and resistance to PIs and INSTIs increased from 2018. Therefore, continuous monitoring of ARV resistance pattern is necessary.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/89/ic-55-328.PMC10551708.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9573765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Norovirus Infection in Children with Acute Lymphoblastic Leukemia.","authors":"Nalla Anuraag Reddy,&nbsp;Keerthi Raj,&nbsp;Harsha Prasada Lashkari","doi":"10.3947/ic.2023.0058","DOIUrl":"https://doi.org/10.3947/ic.2023.0058","url":null,"abstract":"<p><p>Norovirus infection in children on treatment for acute lymphoblastic leukemia can lead to severe morbidity due to chronic viral shedding, malabsorption, failure to thrive, and interruption of chemotherapy. We had four children with norovirus diarrhoea in eight years period in our pediatric oncology unit. Three children under two years of age had chronic noroviral shedding and persistent diarrhoea, probably due to poor adaptive immune responses. Two of those children didn't respond to nitazoxanide and succumbed to the illness. The third patient who received nitazoxanide and favipiravir, is currently well on chemotherapy.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/95/ic-55-403.PMC10551709.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41123442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Service Delivery in the Philippines during the COVID-19 Pandemic.","authors":"Dalmacito A Cordero","doi":"10.3947/ic.2023.0081","DOIUrl":"10.3947/ic.2023.0081","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/ed/ic-55-408.PMC10551721.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1.","authors":"Sang-Kyu Shin, Jung-Eun Cho, Eun-Bin Lee, Yeon-Sook Kim, Sook-In Jung","doi":"10.3947/ic.2022.0176","DOIUrl":"10.3947/ic.2022.0176","url":null,"abstract":"<p><strong>Background: </strong>Abacavir/dolutegravir/lamivudine has been indicated in Korea since 2015 for treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination. This regulatory post-marketing surveillance (PMS) study evaluated the real-life safety and effectiveness of abacavir/dolutegravir/lamivudine in patients with HIV-1 in clinical practice in Korea.</p><p><strong>Materials and methods: </strong>This open-label post-marketing surveillance examined data from consecutive patients (aged ≥12 years) with HIV-1 infection receiving abacavir/dolutegravir/lamivudine according to locally approved prescribing information; treatment-naïve and treatment-experienced patients were permitted. Data regarding patient demographics, medical history, clinical characteristics, medications (HIV-1 related and concomitant), resource utilization and comorbidities were extracted from patient records over a 1-year treatment period. Outcomes included safety of abacavir/dolutegravir/lamivudine (primary endpoint) and real-life effectiveness according to physician's global assessment and the proportion of patients with plasma HIV-1 RNA count <50 copies/mL at 48 weeks.</p><p><strong>Results: </strong>Of 663 patients treated with abacavir/dolutegravir/lamivudine at 27 centers in Korea (June 2015 - June 2021), 656 were eligible for the safety analyses and 484 for effectiveness analyses. Patients were mostly male (94.8%) mean age was 42.2 ± 14.0 years and mean weight was 68.1 ± 11.0 kg. Adverse events (AEs, n = 656 in total) were mostly mild in severity, with the most common being nasopharyngitis (7.9%), retching (7.5%), headache (4.9%). Of 121 adverse drug reactions (ADRs), the most frequent were retching (4.4%), headache (1.8%) and dizziness (1.7%). Of 55 serious AEs, the most frequent were anogenital warts (1.1%). Of 2 serious ADRs, nothing was unexpected, and both resolved. The risk of experiencing an AE while receiving abacavir/dolutegravir/lamivudine appeared to be especially increased in patients receiving concomitant medications for other conditions. Abacavir/dolutegravir/lamivudine effectively suppressed HIV-1 (96.1% of patients had plasma HIV-1 RNA <50 copies/mL), and 99.0% of patients showed symptom improvement based on physician assessment.</p><p><strong>Conclusion: </strong>Results of this PMS study showed that abacavir/dolutegravir/lamivudine administered as highly active antiretroviral therapy was well tolerated and effective in patients with HIV-1 infection.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/42/ic-55-337.PMC10551717.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9573764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiologic and Clinical Characteristics of Patients with Severe Fever with Thrombocytopenia Syndrome at Tertiary Hospital in Jeju for 10 years.","authors":"Jae Yeon Kim,&nbsp;Jeong Rae Yoo,&nbsp;Misun Kim,&nbsp;Hyunjoo Oh,&nbsp;Sang Taek Heo","doi":"10.3947/ic.2023.0035","DOIUrl":"10.3947/ic.2023.0035","url":null,"abstract":"<p><strong>Background: </strong>Severe fever with thrombocytopenia syndrome (SFTS), which was first discovered in China in 2009, is an infectious disease with a high mortality rate, particularly in East Asia. This study aimed to investigate the epidemiological and clinical characteristics and risk factors for mortality by analyzing SFTS cases accumulated for up to ten years in Jeju, Korea.</p><p><strong>Materials and methods: </strong>Medical records of patients diagnosed with SFTS between March 2013 and August 2022 at a tertiary hospital in Jeju were analyzed retrospectively. We investigated data of patients with SFTS on the epidemiologic and clinical characteristics, laboratory findings, and administered treatments and compared the differences between fatal and non-fatal groups.</p><p><strong>Results: </strong>We enrolled 91 SFTS-confirmed patients. The median age of patients was 62 years, and the fatality rate increased with age (<i>P</i> = 0.004). Fever was the most common symptom (84.6%), and diarrhea (37.4%) was also present in some cases. The overall fatality rate was 10.9%. Dyspnea (20.0% <i>vs.</i> 0.0%, <i>P</i> = 0.009) and changes in mental status (70.0% <i>vs.</i> 11.0%, <i>P</i> <0.001) were more frequent in fatal cases. Risk factor assessment revealed that a high aspartate aminotransferase /alanine aminotransferase ratio (odds ratio [OR]: 39.568, 95% confidence interval [CI]: 1.479 - 1,058.639, <i>P</i> = 0.028) and elevated total bilirubin levels (OR: 53.037, 95% CI: 1.064 - 2,643.142, <i>P</i> = 0.046) were also significantly associated with fatal cases. Plasma exchange (40.7%) was the most commonly administered treatment.</p><p><strong>Conclusion: </strong>SFTS has a high mortality rate; therefore, awareness of SFTS must be raised among physicians and citizens living in tick-inhabited areas, such as Jeju.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/bc/ic-55-377.PMC10551713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10242530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seroprevalence of Measles IgG Antibodies in Married Immigrant Women from Multicultural Families in Korea.","authors":"Woojoo Lee,&nbsp;Mi Yeong Shin,&nbsp;Eunbyeul Go,&nbsp;Hyun-Cheol Lim,&nbsp;Ji-Yoon Jeon,&nbsp;Yerim Kwon,&nbsp;Yerin Lee,&nbsp;Tong-Soo Kim,&nbsp;Sung-Keun Lee,&nbsp;Young Yil Bahk","doi":"10.3947/ic.2023.0026","DOIUrl":"10.3947/ic.2023.0026","url":null,"abstract":"<p><strong>Background: </strong>Although an effective vaccine has been available, measles still causes mast morbidity and mortality world widely. In Korea, a small number of measles cases have been reported through exposure to imported cases among young people with vaccine-induced measles immunity. Recently due to international migration including marriage, marriage migrants were the second-largest group of foreign population in Korea. Our study was carried out to obtain positive rate of measles antibody among married immigrant women from 12 countries in 10 Gun-Counties and 6 Cities, Korea.</p><p><strong>Materials and methods: </strong>A total of 547 blood samples were collected from maternal multicultural members from 12 countries. The measles-specific IgG antibody was measured by ELISA (Enzyme-linked immunosorbent assay; Enzygnost^® Anti-measles virus/IgG, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). We performed a simple logistic regression to test whether the measles antibody seroprevalence differed by participant age, location, or country of birth and then calculated the likelihood ratio statistics to determine whether measles antibody seroprevalence differed by country of birth.</p><p><strong>Results: </strong>Overall positive measles seroprevalence was 75.3% (95% confidence interval: 71.7 - 78.9). Participants aged 20 - 24 years, 25 - 29 years, and 30 - 63 years has respective seropositivities of 52.5%, 55.3%, and 82.7%. In this study, the geometric mean titers of participants aged 21 - 29 years were slightly lower than those of participants aged over 30 years, which were 1,372 mIU/ml and 2,261 mIU/ml, respectively (average of total participants: 2,027 mIU/ml).</p><p><strong>Conclusion: </strong>The study provides detailed information about seroimmunity of the married immigrant population in Korea, which is important for measles elimination. Since the 1980s, most vaccine-preventable diseases including measles have been well-controlled. Nevertheless, sporadic measles outbreaks are still reported. Thus, special attention should be paid to the possible importation of infectious diseases such as measles by immigration.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/c0/ic-55-368.PMC10551720.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10259990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying the Unmet Medical Needs of HIV-Positive Subjects in Korea: Results of a Nationwide Online Survey.","authors":"Jeong-A Lee,&nbsp;Yeni Kim,&nbsp;Joo Yeon Lee,&nbsp;Sejun Park,&nbsp;Jun-Yong Choi","doi":"10.3947/ic.2023.0065","DOIUrl":"10.3947/ic.2023.0065","url":null,"abstract":"<p><p>An online survey was conducted in Korea to identify the unmet medical needs of people living with human immunodeficiency virus (HIV) (PLWH). Participants (n = 105) were mostly male (93.3%), aged >40 years (75.2%), and treated for ≥6 years post-diagnosis (61.9%). Most PLWH (71.4%) were very satisfied/satisfied with their HIV management. Areas of concern were quality of life (QoL) and mental health. Characteristics of a long-term therapeutic agent were 'low risk of resistance', 'high long-term viral suppression efficacy', and 'high degree of safety'. Pre-consultation QoL and mental health screening would be beneficial for the long-term success of HIV management.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/e5/ic-55-397.PMC10551716.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41140271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigating from COVID-19 during Intercollegiate Sports Match.","authors":"Young June Choe,&nbsp;In Han Song,&nbsp;Kabsung Kim,&nbsp;Seunghun Hyun,&nbsp;Hee-Deung Park,&nbsp;Yun-Kyung Kim","doi":"10.3947/ic.2023.0047","DOIUrl":"10.3947/ic.2023.0047","url":null,"abstract":"<p><p>The coronavirus disease 2019 pandemic has posed a significant threat not only to health outcomes but also to other societal sectors, including the educational system. Apart from youth education, colleges and universities are characterized by the integration of in-depth theoretical and practical knowledge in young adulthood. Our observations in this study suggest that college fairs, sports matches, and extracurricular activities can be safely resumed when population-level immunity has reached herd protection.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/56/ic-55-394.PMC10551711.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10169905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Using Bacteriophage Therapy to Reduce Morbidity and Mortality Associated with Spinal Epidural Abscesses.","authors":"James B Doub,&nbsp;Jeremy Tran,&nbsp;Ryan Smith,&nbsp;Tyler Pease,&nbsp;Eugene Koh,&nbsp;Stephen Ludwig,&nbsp;Alina Lee,&nbsp;Ben Chan","doi":"10.3947/ic.2022.0168","DOIUrl":"https://doi.org/10.3947/ic.2022.0168","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to determine the feasibility of using bacteriophage therapeutics in spinal epidural abscess (SEA) by reviewing the causes and outcomes of SEA at a single institution and testing a bacteriophage for activity against preserved SEA clinical isolates.</p><p><strong>Materials and methods: </strong>Medical records were reviewed of patients that received incision and drainage for SEA at a single medical center. Causative organisms, incidence of coinciding bacteremia and outcomes were recorded. A subset of SEA patients (N = 11), that had preserved clinical isolates, were assessed to evaluate if a bacteriophage therapeutic had ample activity to those isolates as seen with spot tests and growth inhibition assays.</p><p><strong>Results: </strong><i>Staphylococcus aureus</i> was the predominate bacterial cause (71%) and bacteremia was associated with 96% of <i>S. aureus</i> SEA. Over 50% of the patients either died within three months, had recurrence of their infection, required repeat debridement, or had long term sequalae. A single bacteriophage had positive spot tests for all the <i>S. aureus</i> clinical isolates and inhibited bacterial growth for more than 24 hours for 9 of the 11 (82%) clinical isolates.</p><p><strong>Conclusion: </strong>SEA is associated with significant mortality and morbidity making this a potential indication for adjuvant bacteriophage therapeutics. Since <i>S. aureus</i> is the predominate cause of SEA and most cases are associated bacteremia this creates a potential screening and treatment platform for Staphylococcal bacteriophages therapeutics, allowing for potential pilot studies to be devised.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/e2/ic-55-257.PMC10323537.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10179854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}